MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PTN stock logo

PTN

Palatin Technologies, Inc.

$8.6
-0.41
 (-4.55%)
Exchange:  NASDAQ
Market Cap:  15.302M
Shares Outstanding:  9.466M
Delayed data
Calculate PTN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Carl Spana
Full Time Employees:  25
Address: 
301 Carnegie Center Drive
Princeton
NJ
8540
US
Website:  https://palatin.com
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Click to read more…

Revenue Segmentation

MarketSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
PTPTN logoPTNPalatin Technologies, Inc.15.3M——-125.4%
ACACTU logoACTUActuate Therapeutics Inc14.6M——-1,490.0%
LILIMN logoLIMNLiminatus Pharma, Inc. Class A Common …16.5M——2,943.1%
BLBLRX logoBLRXBioLineRx Ltd.12.1M——-44.4%
KZKZIA logoKZIAKazia Therapeutics Limited11.2M——-948.5%
ININAB logoINABIN8bio, Inc.10.8M——-128.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/11/13 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue4,490.090013,185.031
Gross Profit4,392.453013,122.352
EBITDA-29,379.924-17,033.407-8,605.609
Operating Income-22,496.121-17,459.939-8,668.288
Net Income-29,736.113-17,307.349-8,377.895

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets10,742.2663,266.9548,523.854
Total Liabilities10,853.7638,043.9991,837.389
Total Stockholders Equity-111.497-4,777.0456,686.465
Total Debt590.338163.781223.679
Cash and Cash Equivalents9,527.3962,564.2657,492.014

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow-31,461.441-21,306.637-13,533.270
Capital Expenditure-42.5260-51.299
Free Cash Flow-31,503.967-21,306.637-13,584.569
Net Income-29,736.113-17,307.349-8,377.895
Net Change in Cash1,537.814-6,963.1314,927.749

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)26,136.830Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)43,561.383Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)31,945Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)1,821.238Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)3,064.720Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)2,235.732Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,057.894Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,040.245Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,385.344Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)98,519.154Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)164,198.589Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)120,412.245Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.490Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.720Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.370Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.16
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-1.64
?Enterprise Value
 (TTM)
: 
8.033M  ?EV/FCF
 (TTM)
: 
-0.59
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-115%  ?ROIC
 (TTM)
: 
-125.44%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.03
?P/B
 (TTM)
: 
5.04  ?Current Ratio
 (TTM)
: 
4.61

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates PTN intrinsic value between $6.45 – $8.65 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about PTN valuation

Is Palatin Technologies, Inc. (PTN) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Palatin Technologies, Inc. (PTN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PTN a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PTN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PTN’s P/E ratio?

You can see PTN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PTN?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PTN a good long-term investment?

Whether PTN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

PTN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-4.55
MarketSnap

Trading Metrics:

Open: 8.93   Previous Close: 9.01
Day Low: 8.48   Day High: 9.2
Year Low: 5.61   Year High: 31
Price Avg 50: 9.99   Price Avg 200: 14.86
Volume: 31409   Average Volume: 50158

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
28-09-2026 14:33
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
06-08-2026 09:40
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read